During the last session, Esperion Therapeutics Inc. (NASDAQ:ESPR)’s traded shares were 5.36 million, with the beta value of the company hitting 0.87. At the end of the trading day, the stock’s price was $2.13, reflecting an intraday gain of 1.91% or $0.04. The 52-week high for the ESPR share is $3.40, that puts it down -59.62 from that peak though still a striking 67.14% gain since the share price plummeted to a 52-week low of $0.70. The company’s market capitalization is $362.99M, and the average trade volume was 6.26 million shares over the past three months.
Esperion Therapeutics Inc. (NASDAQ:ESPR) trade information
Esperion Therapeutics Inc. (ESPR) registered a 1.91% upside in the last session and has traded in the green over the past 5 sessions. The stock spiked 1.91% in intraday trading to $2.13, hitting a weekly high. The stock’s 5-day price performance is 15.76%, and it has moved by -18.70% in 30 days. Based on these gigs, the overall price performance for the year is 74.59%.
Esperion Therapeutics Inc. (ESPR) estimates and forecasts
Statistics show that Esperion Therapeutics Inc. has outperformed its competitors in share price, compared to the industry in which it operates. Esperion Therapeutics Inc. (ESPR) shares have gone up 167.79% during the last six months, with a year-to-date growth rate more than the industry average at 66.50% against 10.10. Yet analysts are ramping up their growth forecast for the fiscal year 2024. Revenue is predicted to grow 106.30% this quarter and then jump 54.30% in the quarter after that. In the rating firms’ projections, revenue will increase 127.90% compared to the previous financial year.
Revenue for the current quarter is expected to be $84.51 million as predicted by 8 analyst(s). Meanwhile, a consensus of 8 analyst(s) estimates revenue growth to $42.53 million by the end of Jun 2024. As per earnings report from last fiscal year’s results, sales for the corresponding quarters totaled $24.33 million and $25.79 million respectively. In this case, analysts expect current quarter sales to grow by 247.40% and then jump by 64.90% in the coming quarter.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings grew an estimated 23.09%. While earnings are projected to return 80.92% in 2024, the next five years will return 16.90% per annum.
ESPR Dividends
Esperion Therapeutics Inc. is due to release its next quarterly earnings in May. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
